Key facts
- Dianosic’s last known valuation is $8.2M (Oct 2022).
- It has raised $15.0M; the latest was Debt - General in Jan 2025.
- Notable investors include Bpifrance, Noshaq, Capital Grand Est, Caisse d'Epargne, Banque Populaire Rives de Paris — 17 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 17 names
- ·Watchlist + deal alerts for Dianosic
- ·The full record, as it builds
Funding rounds
No funding rounds for Dianosic are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Dianosic
Developer of medical devices designed to serve in the treatment of ENT conditions. The company's platform offers an alternative to daily medication by designing a unique sustained intranasal drug delivery solution for respiratory and chronic central nervous system diseases, its active resorbable intranasal scaffold device includes asymmetric balloons to treat nosebleeds and active resorbable scaffolds that treat chronic sinusitis, allergic rhinitis, and intranasal bleeding, enabling doctors to remotely follow patients out of the hospital and keep track of their health.
- Sector
- Healthcare
- HQ
- Strasbourg, France
- Founded
- 2017
- Employees
- 12
- Website
- dianosic.com/
- Ownership
- Privately Held (backing)
Dianosic doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Dianosic shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Dianosic in its N-PORT filings yet. We sweep new filings monthly.